MIRA Pharmaceuticals, Inc.
MIRA
$0.78
$0.000.61%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 450.30K | 578.70K | 5.33M | 904.30K | 1.05M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.16M | 1.10M | 5.82M | 1.32M | 1.55M |
| Operating Income | -1.16M | -1.10M | -5.82M | -1.32M | -1.55M |
| Income Before Tax | -1.21M | -1.15M | -5.98M | -1.14M | -1.54M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -1.21M | -1.15M | -5.98M | -1.14M | -1.54M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.21M | -1.15M | -5.98M | -1.14M | -1.54M |
| EBIT | -1.16M | -1.10M | -5.82M | -1.32M | -1.55M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -0.03 | -0.03 | -0.15 | -1.18 | -0.09 |
| Normalized Basic EPS | -0.02 | -0.02 | -0.09 | -0.04 | -0.06 |
| EPS Diluted | -0.03 | -0.03 | -0.15 | -1.18 | -0.09 |
| Normalized Diluted EPS | -0.02 | -0.02 | -0.09 | -0.04 | -0.06 |
| Average Basic Shares Outstanding | 42.02M | 41.94M | 40.82M | 19.27M | 16.99M |
| Average Diluted Shares Outstanding | 42.02M | 41.94M | 40.82M | 19.27M | 16.99M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |